PT854914E - Vacinas vivas contra agentes patogenicos gram-negativos expressando o-antigenes heterologos - Google Patents

Vacinas vivas contra agentes patogenicos gram-negativos expressando o-antigenes heterologos

Info

Publication number: PT854914E
Authority: PT; Portugal
Prior art keywords: heterologous; negative; strains; antigens; gram
Prior art date: 1995-10-13

Application number

PT96934548T

Other languages

English (en)

Inventor

Jean-Francois Viret

Didier Favre

Stanley J Cryz

Original Assignee

Berna Biotech Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-13

Filing date

1996-10-04

Publication date

2004-08-31

1996-10-04 Application filed by Berna Biotech Ag filed Critical Berna Biotech Ag

2004-08-31 Publication of PT854914E publication Critical patent/PT854914E/pt

Links

229960005486 vaccine Drugs 0.000 title abstract 4
239000000427 antigen Substances 0.000 title abstract 2
239000003795 chemical substances by application Substances 0.000 title 1
108090000623 proteins and genes Proteins 0.000 abstract 3
AAXCQFOXUJMCCW-PETQGJDISA-N LPS core Chemical compound O([C@H]1[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]([C@@H](CO[C@]2(O[C@@H]([C@@H](OC3[C@H]([C@@H](OC4[C@H]([C@@H](OC5[C@@H]([C@@H](O[C@@H]6[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O6)OC6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)NC(C)=O)[C@H](O)[C@@H](CO[C@@H]6[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O6)O)O5)O)[C@H](O)[C@@H]([C@@H](O)COC5[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O5)O)O4)O)[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)O3)O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](O[C@]4(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C4)[C@@H](O)CO)C(O)=O)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)O1)OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C[C@H]1O[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H]1O AAXCQFOXUJMCCW-PETQGJDISA-N 0.000 abstract 1
230000002238 attenuated effect Effects 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000002950 deficient Effects 0.000 abstract 1
238000012217 deletion Methods 0.000 abstract 1
230000037430 deletion Effects 0.000 abstract 1
244000000021 enteric pathogen Species 0.000 abstract 1
238000012239 gene modification Methods 0.000 abstract 1
230000005017 genetic modification Effects 0.000 abstract 1
235000013617 genetically modified food Nutrition 0.000 abstract 1
244000000058 gram-negative pathogen Species 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PT96934548T 1995-10-13 1996-10-04 Vacinas vivas contra agentes patogenicos gram-negativos expressando o-antigenes heterologos PT854914E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP95116208		1995-10-13

Publications (1)

Publication Number	Publication Date
PT854914E true PT854914E (pt)	2004-08-31

Family

ID=8219717

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT96934548T PT854914E (pt)	1995-10-13	1996-10-04	Vacinas vivas contra agentes patogenicos gram-negativos expressando o-antigenes heterologos

Country Status (14)

Country	Link
US (1)	US6613321B1 (pt)
EP (1)	EP0854914B1 (pt)
JP (1)	JP4189031B2 (pt)
KR (1)	KR100451104B1 (pt)
AT (1)	ATE263832T1 (pt)
AU (1)	AU724002B2 (pt)
CA (1)	CA2232563C (pt)
DE (1)	DE69632141T2 (pt)
DK (1)	DK0854914T3 (pt)
ES (1)	ES2218602T3 (pt)
GR (1)	GR950300072T1 (pt)
MX (1)	MX9802881A (pt)
PT (1)	PT854914E (pt)
WO (1)	WO1997014782A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6399074B1 (en) *	1998-07-24	2002-06-04	Megan Health, Inc.	Live attenuated salmonella vaccines to control avian pathogens
EP1372707A1 (en) *	2001-04-06	2004-01-02	Institut Pasteur	Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of vibrio cholerae 0139 bound to tetanus toxoid
US20080124355A1 (en)	2006-09-22	2008-05-29	David Gordon Bermudes	Live bacterial vaccines for viral infection prophylaxis or treatment
US8647642B2 (en)	2008-09-18	2014-02-11	Aviex Technologies, Llc	Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US8241623B1 (en)	2009-02-09	2012-08-14	David Bermudes	Protease sensitivity expression system
US8771669B1 (en)	2010-02-09	2014-07-08	David Gordon Bermudes	Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en)	2010-02-09	2017-03-21	David Gordon Bermudes	Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en)	2010-02-09	2013-09-03	David Gordon Bermudes	Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9593339B1 (en)	2013-02-14	2017-03-14	David Gordon Bermudes	Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9737592B1 (en)	2014-02-14	2017-08-22	David Gordon Bermudes	Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en)	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US10806778B2 (en) *	2019-01-30	2020-10-20	Prokarium Limited	Modified strain of Salmonella enterica Typhi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1217303B (it) *	1984-02-01	1990-03-22	Enterovax Res Pty Ltd	Ceppi batterici particolarmente utili per la produzione di vaccini per il trattamenmto di malattie intestinali e simili e metodo di ingegneria gentica per la produzione dei detti vaccini
US5110588A (en) *	1986-08-19	1992-05-05	Enterovax Limited	Composite salmonella E. coli, Vibrio cholerae vaccine strains
DE69221120T2 (de) *	1992-04-10	1998-02-26	Schweiz Serum & Impfinst	Rekombinanter lebender Impfstoff gegen Gram-negative enterische Pathogene
DE4221840A1 (de) *	1992-07-03	1994-01-05	Biotechnolog Forschung Gmbh	Bivalente Lebendvakazine gegen bakterielle Darmpathogene, Herstellungsverfahren sowie Plasmide und Stämme als Ausgangsmaterial

1996
- 1996-01-31 GR GR950300072T patent/GR950300072T1/el unknown
- 1996-10-04 ES ES96934548T patent/ES2218602T3/es not_active Expired - Lifetime
- 1996-10-04 US US09/051,536 patent/US6613321B1/en not_active Expired - Lifetime
- 1996-10-04 JP JP51547097A patent/JP4189031B2/ja not_active Expired - Lifetime
- 1996-10-04 EP EP96934548A patent/EP0854914B1/en not_active Expired - Lifetime
- 1996-10-04 AU AU72859/96A patent/AU724002B2/en not_active Ceased
- 1996-10-04 AT AT96934548T patent/ATE263832T1/de active
- 1996-10-04 KR KR10-1998-0702715A patent/KR100451104B1/ko not_active Expired - Fee Related
- 1996-10-04 WO PCT/EP1996/004334 patent/WO1997014782A1/en not_active Ceased
- 1996-10-04 PT PT96934548T patent/PT854914E/pt unknown
- 1996-10-04 DK DK96934548T patent/DK0854914T3/da active
- 1996-10-04 DE DE69632141T patent/DE69632141T2/de not_active Expired - Lifetime
- 1996-10-04 CA CA2232563A patent/CA2232563C/en not_active Expired - Fee Related
1998
- 1998-04-13 MX MX9802881A patent/MX9802881A/es active IP Right Grant

Also Published As

Publication number	Publication date
KR19990064228A (ko)	1999-07-26
AU7285996A (en)	1997-05-07
JP2000506368A (ja)	2000-05-30
CA2232563C (en)	2011-12-06
DK0854914T3 (da)	2004-07-26
MX9802881A (es)	1998-11-30
WO1997014782A1 (en)	1997-04-24
ES2218602T3 (es)	2004-11-16
JP4189031B2 (ja)	2008-12-03
GR950300072T1 (en)	1996-01-31
US6613321B1 (en)	2003-09-02
DE69632141D1 (de)	2004-05-13
AU724002B2 (en)	2000-09-07
ATE263832T1 (de)	2004-04-15
EP0854914B1 (en)	2004-04-07
KR100451104B1 (ko)	2005-06-13
EP0854914A1 (en)	1998-07-29
DE69632141T2 (de)	2005-03-31
CA2232563A1 (en)	1997-04-24

Publication	Publication Date	Title
PT854914E (pt)	2004-08-31	Vacinas vivas contra agentes patogenicos gram-negativos expressando o-antigenes heterologos
Saxena et al.	2013	Pre-existing immunity against vaccine vectors–friend or foe?
Milton et al.	1996	Flagellin A is essential for the virulence of Vibrio anguillarum
GR3025258T3 (en)	1998-02-27	Live vaccines
Moreno et al.	2010	Salmonella as live trojan horse for vaccine development and cancer gene therapy
ATE219948T1 (de)	2002-07-15	Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
MX9703017A (es)	1997-10-31	Inmunizacion oral con plantas transgenicas.
RU95105518A (ru)	1997-03-27	Применение мутантов вируса герпеса, вакцина
WO1998056901A3 (en)	1999-03-18	Live attenuated vaccines
EP0841941A4 (en)	2001-11-14	Novel non-pyrogenic bacterial strains and their use
JP2002524077A (ja)	2002-08-06	抗原キャリヤーとしての弱毒化サルモネラｓｐｉ２突然変異体
WO2002062378A3 (en)	2003-05-01	Hyperblebbing bacterial strains and use thereof for production of vaccines
CY1107950T1 (el)	2013-09-04	Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι
Gentschev et al.	2000	Delivery of protein antigens and DNA by virulence-attenuated strains of Salmonella typhimurium and Listeria monocytogenes
Dunstan et al.	2003	In vitro and in vivo stability of recombinant plasmids in a vaccine strain of Salmonella enterica var. Typhimurium
Sousa	2003	Pathogenicity mechanisms of prokaryotic cells: an evolutionary view
DE69333751D1 (de)	2005-03-10	Nicht-verbreitendes lebendes herpesvirusvakzin
CA2197804C (fr)	2010-11-16	Procede de production de proteines recombinantes, plasmides et cellules modifiees
Qimron et al.	2004	Identification of Salmonella typhimurium genes responsible for interference with peptide presentation on MHC class I molecules: Δyej Salmonella mutants induce superior CD8+ T‐cell responses
JP2693948B2 (ja)	1997-12-24	侵入性微生物
EP1322327B1 (en)	2008-06-04	Stabilisation of plasmid inheritance in bacteria by preventing multimerisation
GB2331521A (en)	1999-05-26	Vaccine preparations
AU2001292051A1 (en)	2002-06-27	Stabilisation of plasmid inheritance in bacteria by preventing multimerisation
CU22835A3 (es)	2006-12-15	Cepas portadoras de vacunas vivas útiles para la expresión a alto nivel de o-antígenos heterólogos de patógenos gram-negativos y derivados de los mismos para usarse como vacunas vivas
FR2809960B1 (fr)	2004-04-23	Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante